TriSalus Life Sciences (NASDAQ:TLSI) Upgraded by Wall Street Zen to "Hold" Rating

Key Points

• TriSalus Life Sciences was upgraded from a "sell" rating to a "hold" rating by Wall Street Zen, signaling a potential improvement in investor sentiment.
• The company reported a quarterly loss of ($0.27) earnings per share, which was worse than the expected loss of ($0.22), although their revenue of $11.21 million exceeded analysts' expectations.
• Institutional investors are actively engaging with TriSalus, with notable increases in stakes from firms like Nantahala Capital Management LLC and Geode Capital Management LLC during the second quarter.

Wall Street Zen upgraded shares of TriSalus Life Sciences (NASDAQ:TLSI - Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday.

TriSalus Life Sciences Trading Down 0.2%

TLSI stock traded down $0.01 during mid-day trading on Friday, reaching $4.87. The company's stock had a trading volume of 6,548 shares, compared to its average volume of 71,975. The company has a market cap of $242.87 million, a price-to-earnings ratio of -4.13 and a beta of 0.49. The business's 50 day moving average price is $4.63 and its 200 day moving average price is $5.09. TriSalus Life Sciences has a 12 month low of $3.42 and a 12 month high of $5.88.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). The business had revenue of $11.21 million during the quarter, compared to analyst estimates of $10.69 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS. As a group, equities analysts expect that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

Institutional Investors Weigh In On TriSalus Life Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE increased its holdings in shares of TriSalus Life Sciences by 1.8% during the second quarter. Bank of America Corp DE now owns 188,906 shares of the company's stock valued at $1,030,000 after acquiring an additional 3,374 shares in the last quarter. Connective Capital Management LLC increased its holdings in shares of TriSalus Life Sciences by 12.8% during the second quarter. Connective Capital Management LLC now owns 32,796 shares of the company's stock valued at $179,000 after acquiring an additional 3,717 shares in the last quarter. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of TriSalus Life Sciences during the second quarter valued at approximately $29,000. Northern Trust Corp increased its holdings in shares of TriSalus Life Sciences by 22.7% during the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company's stock valued at $161,000 after acquiring an additional 5,936 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company's stock valued at $41,000 after acquiring an additional 7,519 shares in the last quarter. Institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.